Vertex Pharmaceuticals Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Vertex Pharmaceuticals Inc 公司

公司簡介

公司代碼VRTX

公司名稱Vertex Pharmaceuticals Inc

上市日期Jul 24, 1991

成立日期1989

CEODr. Reshma Kewalramani

員工數量6100

證券類型Ordinary Share

年結日Jul 24

公司地址50 Northern Avenue

城市BOSTON

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編02210

電話16173416393

網址https://www.vrtx.com/

公司代碼VRTX

上市日期Jul 24, 1991

成立日期1989

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Bruce I. Sachs

Lead Independent Director

40.00K

--

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.66K

+40.46%

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

30.14K

--

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

25.25K

+59.69%

Mr. Stuart A. Arbuckle

Chief Operating Officer, Executive Vice President

17.10K

+342.84%

Mr. Lloyd A. Carney

Independent Director

6.31K

+18.82%

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.43K

--

Ms. Diana L. Mckenzie

Independent Director

1.47K

-10.17%

Mr. Michel Lagarde

Independent Director

1.13K

--

Ms. Kristen Ambrose

Senior Vice President, Chief Accounting Officer

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Bruce I. Sachs

Lead Independent Director

40.00K

--

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.66K

+40.46%

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

30.14K

--

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

25.25K

+59.69%

Mr. Stuart A. Arbuckle

Chief Operating Officer, Executive Vice President

17.10K

+342.84%

Mr. Lloyd A. Carney

Independent Director

6.31K

+18.82%

收入明細

單位: USD更新時間: 3月5日週三

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

TRIKAFTA

10.23B

92.90%

Other CF products

781.50M

7.09%

地區USD

名稱

營收

佔比

United States

6.68B

60.66%

Europe

3.45B

31.34%

Other

881.30M

7.99%

業務

地區

業務USD

名稱

營收

佔比

TRIKAFTA

10.23B

92.90%

Other CF products

781.50M

7.09%

股東統計

更新時間: 2月21日週五

持股股東

股東類型

持股股東

股東統計

佔比

Capital World Investors

11.03%

The Vanguard Group, Inc.

9.01%

BlackRock Institutional Trust Company, N.A.

5.57%

State Street Global Advisors (US)

4.66%

Capital Research Global Investors

4.06%

Other

65.64%

持股股東

股東統計

佔比

Capital World Investors

11.03%

The Vanguard Group, Inc.

9.01%

BlackRock Institutional Trust Company, N.A.

5.57%

State Street Global Advisors (US)

4.66%

Capital Research Global Investors

4.06%

Other

65.64%

股東類型

股東統計

佔比

Investment Advisor

49.08%

Investment Advisor/Hedge Fund

37.63%

Pension Fund

2.66%

Research Firm

2.13%

Bank and Trust

1.87%

Hedge Fund

1.44%

Sovereign Wealth Fund

1.43%

Holding Company

0.19%

Individual Investor

0.12%

Other

3.41%

機構持股

更新時間: 1月19日週日

報告期間

機構數

持股數

持股佔比

持股變動

2025Q1

2803

248.60M

96.81%

-2.22M

2024Q4

2877

248.75M

96.87%

-2.25M

2024Q3

2786

247.86M

96.18%

-4.19M

2024Q2

2747

248.35M

96.27%

-4.14M

2024Q1

2680

247.62M

95.87%

-4.47M

2023Q4

2608

247.92M

96.20%

-4.51M

2023Q3

2477

248.64M

96.45%

-6.19M

2023Q2

2488

248.88M

96.55%

-7.10M

2023Q1

2468

250.11M

97.13%

-4.73M

2022Q4

2454

248.59M

96.73%

-7.79M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Capital World Investors

28.32M

11.03%

+1.51M

+5.65%

Dec 31, 2024

The Vanguard Group, Inc.

23.14M

9.01%

+102.47K

+0.44%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

14.32M

5.57%

-90.57K

-0.62%

Dec 31, 2024

State Street Global Advisors (US)

11.97M

4.66%

+163.15K

+1.38%

Dec 31, 2024

Capital Research Global Investors

10.42M

4.06%

+1.42M

+15.84%

Dec 31, 2024

Fidelity Management & Research Company LLC

9.10M

3.54%

-1.25M

-12.06%

Dec 31, 2024

Wellington Management Company, LLP

5.91M

2.3%

+1.11M

+23.28%

Dec 31, 2024

Geode Capital Management, L.L.C.

5.64M

2.19%

-287.65K

-4.84%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

5.22M

2.03%

+92.09K

+1.79%

Dec 31, 2024

JP Morgan Asset Management

4.61M

1.79%

-403.92K

-8.04%

Dec 31, 2024

持股ETF

更新時間: 16 小時前

機構名稱

佔比

Future Fund Active ETF

13.69%

VanEck Biotech ETF

11.53%

ProShares Ultra Nasdaq Biotechnology

8.36%

Invesco Nasdaq Biotechnology ETF

7.92%

Tema Neuroscience and Mental Health ETF

7.19%

iShares Biotechnology ETF

6.84%

Natixis Loomis Sayles Focused Growth ETF

5.03%

Franklin Genomic Advancements ETF

4.8%

Tema Cardiovascular and Metabolic ETF

4.37%

First Trust NYSE Arca Biotechnology Index Fund

3.64%

Future Fund Active ETF

佔比13.69%

VanEck Biotech ETF

佔比11.53%

ProShares Ultra Nasdaq Biotechnology

佔比8.36%

Invesco Nasdaq Biotechnology ETF

佔比7.92%

Tema Neuroscience and Mental Health ETF

佔比7.19%

iShares Biotechnology ETF

佔比6.84%

Natixis Loomis Sayles Focused Growth ETF

佔比5.03%

Franklin Genomic Advancements ETF

佔比4.8%

Tema Cardiovascular and Metabolic ETF

佔比4.37%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.64%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Vertex Pharmaceuticals Inc

488.440USD

Vertex Pharmaceuticals Inc

488.440

概覽

公司